论文部分内容阅读
作者报告53例急性脑梗死分为类固醇治疗组(27例)、安慰剂组(26例)。平均年龄分别为71±11及73±13岁。两组均以男性为主,且病灶分布相类似,均有8例(16％)脑干梗死。入院时意识障碍情况亦相似,31例入院时嗜睡或昏睡,7例昏迷。41例生存,12例死亡。生存组观察1～29天内神经系统损害的改善率在类固醇组为35.6±25.8％,安慰剂组为16.7±22.4％(P<0.5),提示接受类固醇治疗的病人并不比接受安慰剂治疗者好。安慰剂组5例死亡,其中3例推测为脑水肿;类固醇组7例死亡,3例为明显的不可控制的脑水肿。在类固醇治疗组中有合并吐血3例,7例接受类固醇治疗的糖尿病患者均严重恶
The authors reported 53 patients with acute cerebral infarction were divided into steroid treatment group (27 cases) and placebo group (26 cases). The average age was 71 ± 11 and 73 ± 13 years, respectively. Both groups were predominantly male, with similar distribution of lesions, with infarction of the brainstem in 8 patients (16%). Consciousness disorders were also similar at admission, with 31 drowsiness or lethargy on admission and 7 coma. 41 survived and 12 died. Survival group observed 1 to 29 days of nervous system damage improvement rate was 35.6 ± 25.8% in the steroid group and 16.7 ± 22.4% in the placebo group (P <0.5), suggesting that patients receiving steroids were no better than those receiving placebo . There were 5 deaths in the placebo group, 3 of which were presumed to be cerebral edema; 7 in the steroid group and 3 in significant uncontrollable cerebral edema. There were 3 cases of combined hematemesis in the steroid treatment group and 7 cases of diabetic patients receiving steroid treatment were severely ill